Flutimavir Inhalation Powder Mist may require lifelong medication and may need to be discontinued promptly when serious adverse reactions occur. The main components of Flutimavir Inhalation Powder Mist include an inhaled glucocorticoid (fluticasone furoate), an inhaled beta2 agonist (umeclidinium bromide), and an inhaled M-blocker (vilanterol), which are primarily used for the treatment of chronic obstructive pulmonary disease (COPD). In the absence of complications, long-term maintenance therapy is usually required, possibly for life. Flutimavir may cause an increased incidence of oral Candida infections, hoarseness, urinary retention, or lead to pneumonia, and careful mouth rinsing is required after use to minimize these adverse reactions. In the event of serious adverse reactions such as pneumonia, adjustment of the treatment regimen may be required. In addition, it is contraindicated in people who are allergic to any of the components of the product or who are highly allergic to milk proteins. Flutemavir should be regulated under medical supervision.